ATRA Quote, Trading Chart, Atara Biotherapeutics Inc.
home / stock / atra / atra quote
$15.89 Last:
-0.38% Change Percent:
$16.05 Open:
$15.89 Previous Close:
$16.38 High:
$15.21 Low:
1,091,582 Volume:
03/04/2021 04:35:14 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-04 | 16.05 | 15.89 | 16.38 | 15.21 | 1,091,582 |
| 2021-03-03 | 16.95 | 15.95 | 17.19 | 15.705 | 1,124,896 |
| 2021-03-02 | 16.55 | 16.94 | 18.1 | 16.12 | 2,059,656 |
| 2021-03-01 | 17.14 | 17.105 | 17.5 | 16.72 | 634,968 |
| 2021-02-26 | 16.72 | 16.78 | 17.15 | 16.29 | 803,602 |
| 2021-02-25 | 17.29 | 16.61 | 17.62 | 16.39 | 1,003,721 |
| 2021-02-24 | 16.82 | 17.35 | 17.48 | 16.56 | 495,961 |
| 2021-02-23 | 16.89 | 16.8 | 17.32 | 16.21 | 895,146 |
| 2021-02-22 | 17.76 | 17.22 | 18.19 | 17.14 | 777,181 |
| 2021-02-19 | 17.79 | 17.88 | 18.71 | 17.77 | 464,320 |
| 2021-02-18 | 18.18 | 17.79 | 18.27 | 17.71 | 540,609 |
| 2021-02-17 | 18.39 | 18.31 | 18.64 | 17.54 | 697,399 |
| 2021-02-16 | 19.335 | 18.64 | 19.335 | 18.38 | 477,337 |
| 2021-02-15 | 19.15 | 18.59 | 19.4 | 18.38 | 531,501 |
| 2021-02-12 | 19.15 | 18.59 | 19.4 | 18.38 | 510,584 |
| 2021-02-11 | 19.43 | 19.22 | 19.8 | 18.71 | 567,584 |
| 2021-02-10 | 20.6 | 19.36 | 20.91 | 19.11 | 552,660 |
| 2021-02-09 | 20.75 | 20.37 | 21.2445 | 20.21 | 570,794 |
| 2021-02-08 | 20.39 | 20.72 | 21.85 | 20.16 | 981,244 |
| 2021-02-05 | 19.47 | 20.32 | 20.5151 | 19.34 | 874,913 |
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
Image source: The Motley Fool. Atara Biotherapeutics Inc (NASDAQ: ATRA) Q4 2020 Earnings Call Mar 1, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript ...
-
On track to complete the rolling tab-cel ® BLA submission in Q3 2021 for patients with EBV + PTLD through active and productive discussions with FDA On track with ATA188 Phase 2 RCT (randomized controlled trial) enrollment in patients with progressive forms of MS,...
-
Live Conference Call and Webcast at 4:30 p.m. EST Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumo...